FDA (CBER)
GUIDANCE DRAFT
Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing
Published: 4/14/2026Detected: 4/14/2026
Summary preview
Topic: Status: Draft.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free account#Genome Editing
#Human Gene Therapy
#Next-Generation Sequencing
Official Source Document Source Verified
Access the original document directly from FDA CBER.
More from FDA (CBER)
- Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus: Guidance for Industry11/3/2026
- Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products11/2/2026
- Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management10/27/2026
- Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry10/14/2026
- Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy: Guidance for Industry10/14/2026